Bleximenib — Investigational Agent
Menin Inhibitor · Phase 1/2 · Johnson & Johnson (Janssen Research & Development)
Mechanism of Action
Oral, potent, selective inhibitor of the menin-KMT2A (MLL1) protein-protein interaction. By blocking menin binding, it dislodges the KMT2A transcriptional complex from HOXA9/MEIS1 loci in NPM1-mutant and KMT2A-rearranged acute leukemias, promoting differentiation and loss of leukemic self-renewal.
Investigational Indications
- Relapsed/refractory acute leukemia with KMT2A rearrangement
- Relapsed/refractory NPM1-mutant AML
- Combination with AML-directed therapies (venetoclax/azacitidine, intensive chemo)